BeyondSpring has been granted a patent for a method of treating cancer expressing mutant RAS proteins by administering Plinabulin. The method targets specific mutations in NRAS, HRAS, and KRAS proteins. GlobalData’s report on BeyondSpring gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on BeyondSpring, Cancer treatment biomarkers was a key innovation area identified from patents. BeyondSpring's grant share as of April 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
Treating cancer expressing mutant ras protein with plinabulin
A recently granted patent (Publication Number: US11918574B2) outlines a method for therapeutically treating cancer characterized by the expression of a mutant form of a RAS protein. The method involves administering Plinabulin to a subject in need, with the mutant forms of the RAS protein specified as NRAS, HRAS, or KRAS with specific amino acid substitutions. The cancers targeted by this method include colorectal, pancreatic, renal, lung, liver, breast, prostate, gastrointestinal, peritoneal, melanoma, endometrial, ovarian, cervical, uterine, bladder, glioblastoma, brain metastases, and various other types.
Furthermore, the patent details the administration of Plinabulin in combination with other therapeutic agents such as temozolomide, bevacizumab, and cisplatin, among others. The dosage of Plinabulin ranges from 5 mg/m2 to 150 mg/m2 and can be administered through various routes including orally, intravenously, topically, and intramuscularly. Additionally, the method allows for the co-administration of Plinabulin with radiation therapy to enhance the treatment efficacy. The patent also specifies different mutant forms of RAS proteins and corresponding cancers, providing a comprehensive approach to treating multiple myeloma, endometrial cancer, colorectal cancer, renal cancer, pancreatic cancer, lung cancer, and colon cancer.
To know more about GlobalData’s detailed insights on BeyondSpring, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
